Form 4: Exelixis EVP Aftab Reports Routine Tax-Related Stock Transactions

Exelixis, Inc.'s EVP of Research and Development, Dana Aftab, reported the withholding of 39,205 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Dana Aftab, Executive Vice President of Research and Development at Exelixis, Inc. (EXEL), reported transactions involving the company's common stock.
• On February 15, 2026, 26,485 shares of common stock were withheld by Exelixis, Inc. at a price of $43.92 per share to satisfy tax liabilities. These taxes were associated with the vesting of performance-based restricted stock units awarded on March 4, 2022, for which performance criteria were certified on January 16, 2025.
• Additionally, on February 15, 2026, an extra 12,720 shares of common stock were withheld by Exelixis, Inc. at $43.92 per share to cover taxes related to the vesting of restricted stock units awarded on January 5, 2023.
• Following these transactions, Dana Aftab directly beneficially owns 693,897 shares of common stock.
• This beneficial ownership includes 414,043 shares of Exelixis, Inc. common stock that are expected to be issued upon the vesting of restricted stock units (RSUs) and performance stock units (PSUs) granted on March 31, 2025.
• An additional 5,835 shares are indirectly owned through the Exelixis, Inc. 401(k) Plan, as detailed in a plan statement dated February 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices and tax obligations rather than a strategic move or a direct reflection of company performance.

Future Outlook

The filing indicates that 414,043 shares of Exelixis, Inc. common stock will be issued to the reporting person upon the future vesting of restricted stock units and performance stock units granted on March 31, 2025.

Industry Context

StockSavvy.ai notes that routine Form 4 filings detailing tax-related share withholdings are common for executives receiving equity compensation and typically do not signal a change in company fundamentals or strategic direction within the biotechnology and pharmaceutical industry.

Related Party Transactions

• The withholding of shares by Exelixis, Inc. to satisfy the reporting person's tax obligations related to equity awards is a standard related-party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders may note the executive's continued significant equity holdings, including future vesting awards, which aligns executive interests with shareholder value. However, the specific transactions reported are routine and have minimal direct impact on company operations or immediate share price.

Next Steps

• The 414,043 shares of Exelixis, Inc. common stock included in the beneficial ownership will be issued to the reporting person upon the future vesting of the associated restricted stock units and performance stock units.

Key Dates

Recommendation

This Form 4 filing details routine tax-related share withholdings by an executive upon the vesting of equity awards. Such transactions are standard practice and do not provide new information regarding the company's operational performance, strategic direction, or future prospects that would warrant a change in investment recommendation. The executive retains significant beneficial ownership, including future vesting awards, suggesting continued alignment with company performance.

Keywords

Exelixis, EXEL, Form 4, insider transaction, stock withholding, restricted stock units, RSUs, PSUs, executive compensation, Dana Aftab